Abivax SA (ABVX) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Abivax SA (ABVX) over the past year, gaining 114.3% versus a gain of 2.9%. Protagonist Therapeutics is the larger company by market cap ($9.05 billion vs $7.77 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | PTGX |
|---|---|---|
| Share price | $89.05 | $139.91 |
| Market cap | $7.77B | $9.05B |
| 1-day change | +2.34% | -0.72% |
| YTD return | -33.97% | +60.19% |
| 1-year return | +2.94% | +114.26% |
| 5-year return | — | +351.76% |
| P/E ratio (TTM) | — | 135.83 |
| EPS (TTM) | $-6.08 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $46.02M |
| Revenue growth (YoY) | — | -89.41% |
| Net income (latest FY) | — | $-130.15M |
| Operating margin | — | -343.63% |
| Net margin | — | -282.83% |
| 52-week high | $148.83 | $160.81 |
| 52-week low | $69.81 | $65.75 |
| Distance from 52-week high | -40.17% | -13.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.17% | +24.86% |
| Average volume | 1.11M | 623.06K |
| Shares outstanding | 87.27M | 64.71M |
| Employees | 98 | 141 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed ABVX by 111.3 percentage points over the past year.
- The two companies sit in different sectors: Abivax SA in Healthcare and Protagonist Therapeutics in Health Care.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Healthcare · Biotechnology · 98 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
ABVX vs PTGX FAQ
Which is bigger, Abivax SA or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $9.05B compared with $7.77B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or PTGX?
PTGX returned +114.26% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Protagonist Therapeutics in the same industry?
No. Abivax SA is in the Healthcare sector, while Protagonist Therapeutics is in Health Care.